牛回速归？港股通创新药ETF（520880）早盘急速拉升逾3.6%

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced a rapid surge, with the high-elasticity Hong Kong Stock Connect innovative drug ETF (520880) rising over 3.6% and achieving a transaction volume exceeding 260 million yuan [1] - The ETF had a significant rebound of 2.12% the previous day, with a total of 130 million yuan attracted over four consecutive days, indicating a warming capital environment [1] - Huachuang Securities noted a shift in the innovative drug industry from quantity logic to quality logic, predicting a product-centric phase by 2025, with domestic innovative drug companies' differentiated pipelines and international layouts becoming crucial [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which currently excludes CXO and focuses entirely on innovative drug R&D companies [1] - As of the end of September, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index had a year-to-date increase of 108.14%, outperforming other innovative drug indices [1] - The ETF is the first in the market to track the aforementioned index, with a fund size of 1.806 billion yuan and an average daily transaction volume of 493 million yuan since its listing, making it the largest and most liquid ETF in its category [1]